2016
DOI: 10.1111/bju.13701
|View full text |Cite
|
Sign up to set email alerts
|

Contemporary minimally invasive surgery for adrenal masses: it's not all about (pure) laparoscopy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 7 publications
0
2
0
Order By: Relevance
“…[ 3 ] While the technical ease of resection and the surgeon's instrumentation freedom are discussed in detail in many studies, the anesthetic implications, analgesic needs, and patient outcomes are less studied. [ 4 5 6 7 8 9 ] There is a limitation in literature on the superiority of robot-assisted laparoscopy over conventional laparoscopy in postoperative pain in abdominal surgery.…”
Section: Introductionmentioning
confidence: 99%
“…[ 3 ] While the technical ease of resection and the surgeon's instrumentation freedom are discussed in detail in many studies, the anesthetic implications, analgesic needs, and patient outcomes are less studied. [ 4 5 6 7 8 9 ] There is a limitation in literature on the superiority of robot-assisted laparoscopy over conventional laparoscopy in postoperative pain in abdominal surgery.…”
Section: Introductionmentioning
confidence: 99%
“…As the role of robotic nephroureterectomy for upper urothelial cancer remains under scrutiny, Veccia et al report a systematic review and meta-analysis of comparative outcomes versus more established nephroureterectomy techniques [22]. Robotic surgery is also being explored for adrenal surgery [23], and Ye et al describe a novel adrenal enucleation technique [24]. Moreover, the robotic platform has allowed to replicate in quality and extent lymph node dissections for several genitourinary cancers [25], and a leader group in the field report one of the largest series of primary robotic retroperitoneal lymph node dissection for non-seminomatous germ cell testicular cancer [26].…”
mentioning
confidence: 99%